DNAPrint Genomics Financials
Based on the key indicators related to DNAPrint Genomics' liquidity, profitability, solvency, and operating efficiency, DNAPrint Genomics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.
Understanding current and past DNAPrint Genomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DNAPrint Genomics' financial statements are interrelated, with each one affecting the others. For example, an increase in DNAPrint Genomics' assets may result in an increase in income on the income statement.
DNAPrint Genomics Stock Summary
DNAPrint Genomics competes with Kite Realty, MI Homes, Cardinal Health, GMS, and Hudson Pacific. DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany. DNAPRINT GENOMICS is traded on OTC Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US23324Q1031 |
| Business Address | 1621 West University |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Phone | 941 366 3400 |
| Currency | USD - US Dollar |
DNAPrint Genomics Key Financial Ratios
DNAPrint Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DNAPrint Genomics's current stock value. Our valuation model uses many indicators to compare DNAPrint Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DNAPrint Genomics competition to find correlations between indicators driving DNAPrint Genomics's intrinsic value. More Info.DNAPrint Genomics is one of the top stocks in return on asset category among its peers. It also is one of the top stocks in profit margin category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value DNAPrint Genomics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.DNAPrint Genomics Systematic Risk
DNAPrint Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DNAPrint Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on DNAPrint Genomics correlated with the market. If Beta is less than 0 DNAPrint Genomics generally moves in the opposite direction as compared to the market. If DNAPrint Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DNAPrint Genomics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DNAPrint Genomics is generally in the same direction as the market. If Beta > 1 DNAPrint Genomics moves generally in the same direction as, but more than the movement of the benchmark.
About DNAPrint Genomics Financials
What exactly are DNAPrint Genomics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include DNAPrint Genomics' income statement, its balance sheet, and the statement of cash flows. Potential DNAPrint Genomics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although DNAPrint Genomics investors may use each financial statement separately, they are all related. The changes in DNAPrint Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DNAPrint Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.DNAPrint Genomics July 15, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of DNAPrint Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DNAPrint Genomics. We use our internally-developed statistical techniques to arrive at the intrinsic value of DNAPrint Genomics based on widely used predictive technical indicators. In general, we focus on analyzing DNAPrint Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DNAPrint Genomics's daily price indicators and compare them against related drivers.
| Information Ratio | 0.126 |
Complementary Tools for DNAPrint Stock analysis
When running DNAPrint Genomics' price analysis, check to measure DNAPrint Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNAPrint Genomics is operating at the current time. Most of DNAPrint Genomics' value examination focuses on studying past and present price action to predict the probability of DNAPrint Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNAPrint Genomics' price. Additionally, you may evaluate how the addition of DNAPrint Genomics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |